Advertisement
Research Article

Screening for HIV-Associated Tuberculosis and Rifampicin Resistance before Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study

  • Stephen D. Lawn mail,

    stevelawn@yahoo.co.uk

    Affiliations: The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

    X
  • Sophie V. Brooks,

    Affiliation: The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

    X
  • Katharina Kranzer,

    Affiliations: The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

    X
  • Mark P. Nicol,

    Affiliations: Division of Medical Microbiology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa

    X
  • Andrew Whitelaw,

    Affiliations: Division of Medical Microbiology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa

    X
  • Monica Vogt,

    Affiliation: The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

    X
  • Linda-Gail Bekker,

    Affiliation: The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

    X
  • Robin Wood

    Affiliations: The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, Department of Science and Technology/National Research Foundation Centre of Excellence in Epidemiological Modelling and Analysis, University of Stellenbosch, Cape Town, South Africa

    X
  • Published: July 26, 2011
  • DOI: 10.1371/journal.pmed.1001067

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.

Linked Articles

Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis

David W. Dowdy, Adithya Cattamanchi, Karen R. Steingart, Madhukar Pai
Essay | published 26 Jul 2011 | PLOS Medicine
doi:10.1371/journal.pmed.1001063

GeneXpert—A Game-Changer for Tuberculosis Control?

Carlton A. Evans
Perspective | published 26 Jul 2011 | PLOS Medicine
doi:10.1371/journal.pmed.1001064

Comparison of Xpert MTB/RIF with Other Nucleic Acid Technologies for Diagnosing Pulmonary Tuberculosis in a High HIV Prevalence Setting: A Prospective Study

Lesley E. Scott, Kerrigan McCarthy, Natasha Gous, Matilda Nduna, Annelies Van Rie, Ian Sanne, Willem F. Venter, Adrian Duse, Wendy Stevens
Research Article | published 26 Jul 2011 | PLOS Medicine
doi:10.1371/journal.pmed.1001061